Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 2.43M shares outstanding
ILPolyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue.
It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza.
The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Tomer Izraeli
Founder, Chief Executive Officer & Director
Tidhar Turgeman
Chief Technology Officer
Nir Ben Yosef
Chief Financial Officer & Compliance Officer
Eyal S. Ron
Chief Scientific Officer
Employees
2
Country
IL
Sector
Healthcare
Website
polyrizon-biotech.com
Loading congressional disclosures…
based on 2.43M shares outstanding
IL30d Avg
25.74K
60d Avg
61.97K
90d Avg
61.33K
